EF001 發行人所發行上市權證/可轉換債券的相關信息 發行人所發行上市權證/可轉換債券 不適用 其他信息 其他信息 不適用 發行人董事 於本公告日期，董事會包括執行董事嚴晗先生(主席)、樂拯先生(副主席)及王馳先生；非執行董事馮莉女士；及獨立非執行董事曾 鈺成先生、徐宏喜先生及陳毅馳先生。 第 2 頁 共 2 頁 v 1.1.1 EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 北京同仁堂國藥有限公司 | | 股份代號 | 03613 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 截至2025年12月31日止年度之特別股息及暫停辦理股份過戶登記手續 | | | 公告日期 | 2026年3月20日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 其他 | | 特 ...

EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | | --- | --- | | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | 股票發行人現金股息公告 | | | 發行人名稱 | 北京同仁堂國藥有限公司 | | 股份代號 | 03613 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 截至2025年12月31日止年度之末期股息及暫停辦理股份過戶登記手續 | | | 公告日期 | 2026年3月20日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 末期 | | 股息性質 | 普通股息 | | 財政年末 | 2025年12月31日 | | 宣派股息的報告期末 | 2025年12月31日 | | 宣派股息 | 每 股 0.37 HKD | | 股東批准日期 | 2026年6月10日 | | 香港過戶登記處相關信息 | | | 派息金額及公司預設派發貨幣 | 每 股 0.37 HKD ...

Financial Performance - Revenue for the year ended December 31, 2025, was HKD 1,513,357, a decrease of 6.1% compared to HKD 1,611,644 in 2024[3] - Gross profit decreased by 13.1% to HKD 925,576 from HKD 1,065,329 in the previous year[3] - Annual profit fell by 21.2% to HKD 416,859, down from HKD 529,167 in 2024[3] - Basic and diluted earnings per share decreased to HKD 0.47 from HKD 0.60, a decline of HKD 0.13[3] - The total comprehensive income for the year was HKD 425,083, compared to HKD 510,597 in the previous year[7] - The operating profit for 2025 was HKD 472,239, slightly lower than HKD 576,924 in 2024, representing a decrease of 17.9%[32] - Financial income for 2025 was HKD 46,835, compared to HKD 57,274 in 2024, showing a decline of 18.2%[32] - The annual profit for 2025 was HKD 416,859, down from HKD 529,167 in 2024, a decrease of 21.2%[32] - The net profit for 2025 was HKD 416.9 million, down 21.2% from HKD 529.2 million in 2024[60] - Earnings per share for 2025 were HKD 0.47, a decline of HKD 0.13 from HKD 0.60 in 2024[60] Assets and Liabilities - Cash and bank balances increased by 25.2% to HKD 2,279,224 from HKD 1,819,753 in 2024[4] - Total assets rose by 2.2% to HKD 4,660,738 compared to HKD 4,559,525 in the previous year[4] - Total liabilities decreased from HKD 313,091,000 in 2024 to HKD 291,877,000 in 2025, representing a reduction of approximately 6.8%[9] - Non-current liabilities increased from HKD 77,737,000 in 2024 to HKD 85,029,000 in 2025, an increase of about 9.4%[9] - Current liabilities decreased from HKD 235,354,000 in 2024 to HKD 206,848,000 in 2025, a decline of approximately 12.2%[9] - The company's total equity and liabilities amounted to HKD 4,660,738,000 in 2025, compared to HKD 4,559,525,000 in 2024, indicating a growth of about 2.2%[9] Dividends - Proposed final dividend per share increased to HKD 0.37 from HKD 0.35, a rise of HKD 0.02[3] - The total dividend paid for 2025 is HKD 292,985,000 (HKD 0.35 per share), an increase from HKD 276,243,000 (HKD 0.33 per share) in 2024[50] - The company plans to pay a final dividend of HKD 0.37 per share and a special dividend of HKD 0.03 per share for 2025[60] Segment Performance - The revenue sources are analyzed based on the geographical location of the group's entities, including Hong Kong, Mainland China, and overseas markets[26] - The Hong Kong segment includes retail sales of traditional Chinese medicine products and health supplements, as well as wholesale activities[29] - The Mainland China segment focuses on wholesale health supplements and exclusive distribution of the "Tong Ren Tang" brand products outside of Mainland China[29] - The overseas segment involves retail and wholesale of traditional Chinese medicine products and health supplements, along with providing traditional Chinese medical services[29] - The segment revenue from Hong Kong for 2025 was HKD 942,294, while for mainland China it was HKD 164,873, and overseas revenue was HKD 406,190[30] Research and Development - Research and development expenses increased to HKD 11,615 in 2025 from HKD 9,128 in 2024[42] - The production and R&D base in Hong Kong has obtained GMP, ISO22000, and HACCP certifications, ensuring comprehensive quality control throughout the production process[65] - The launch of the high-end herbal toothpaste series "Gum Nourishing" marks an expansion of the product matrix, with significant achievements in technological innovation[66] - The group has successfully registered a new anti-aging product and received a national invention patent, further enriching its product resource reserves[66] Financial Reporting Standards - The group has adopted the revised Hong Kong Accounting Standard No. 21 regarding "Lack of Convertibility" for the first time, which has no impact on the financial statements as all currencies used in transactions are convertible[19] - The Hong Kong Institute of Certified Public Accountants has issued amendments to various financial reporting standards, which include examples reflecting the existing requirements regarding the use of climate-related disclosures[20] - The group has not yet applied the newly issued but not yet effective financial reporting standards in its financial statements, planning to adopt them when they become effective[21] - The new Hong Kong Financial Reporting Standard No. 18 will replace the previous Standard No. 1, introducing new requirements for the presentation of income and expenses in the profit and loss statement[23] Corporate Strategy and Development - The group aims to capture the global health consumption upgrade trend and is committed to promoting traditional Chinese medicine culture internationally[67] - The group has established a technology innovation system in collaboration with universities, enhancing the modernization and internationalization of traditional Chinese medicine[68] - The group is focusing on core business development, enhancing production quality management and technological innovation to achieve high-quality growth[64] - The group is actively expanding into overseas markets, with the launch of deer products in New Zealand, adhering to traditional production techniques while incorporating standardized processes[67] Employee and Operational Metrics - The group had 780 employees as of December 31, 2025, with employee costs amounting to HKD 224.0 million, a reduction of 10.9% from HKD 251.4 million in 2024[75] - Distribution and selling expenses decreased by 31.0% to HKD 207.1 million, accounting for 13.7% of revenue, down from 18.6% last year[81] - General and administrative expenses reduced by 4.4% to HKD 183.3 million, representing 12.1% of revenue, consistent with last year's 11.9%[82] Taxation - Total income tax expense for 2025 was HKD 87,830, a decrease from HKD 100,606 in 2024[44] - Income tax expense decreased by 12.7% to HKD 87.8 million, with an effective tax rate of 17.4%, up from 16% last year[84] Corporate Governance - The audit committee, consisting of three independent non-executive directors, has reviewed the company's accounting policies and financial performance for the year ending December 31, 2025[101] - The company has adhered to the corporate governance code as stipulated in the listing rules as of December 31, 2025[104] - All directors confirmed compliance with the standards for securities trading as outlined in the listing rules as of December 31, 2025[105]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責 ， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明 ， 並 明 確 表 示 概 不 就 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 依 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任 。 BEIJING TONG REN TANG CHINESE MEDICINE COMPANY LIMITED 北 京 同 仁 堂 國 藥 有 限 公 司 （ 於 香 港 註 冊 成 立 之 有 限 公 司 ） （ 股 份 代 號 ： 3613） 主 席 嚴 晗 香港， 2026 年 3 月 6 日 於本公告日期，董事會成員如下 : 執行董事﹕ 嚴 晗 先 生 （主席） 樂 拯 先 生 （ 副 主 席 ） 王 馳 先 生 陳毅馳先生 獨立非執行董事﹕ 董 事 會 會 議 召 開 日 期 北 京 同 仁 堂 國 藥 有 限 公 司 （ 「 本 公 司 」 ） 董事會 （ 「 董 事 會 」 ） 謹 此 宣 布 ， 本 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2026年2月28日 | 狀態: 新提交 | | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | 公司名稱: | 北京同仁堂國藥有限公司 | | | 呈交日期: | 2026年3月4日 | | | I. 法定/註冊股本變動 不適用 | | | FF301 FF301 II. 已發行股份及/或庫存股份變動及足夠公眾持股量的確認 1. 股份分類 普通股 股份類別 不適用 於香港聯交所上市 (註1) 是 證券代號 (如上市) 03613 說明 已發行股份（不包括庫存股份）數目 庫存股份數目 已發行股份總數 上月底結存 837,100,000 0 837,100,000 增加 / 減少 (-) 0 0 本月底結存 837,100,000 0 837,100,000 足夠公眾持股量的確認(註4) | 根據《主板上市規則》第13.32D(1)條或第19A.28D(1)條 / 《GEM上市規則》第17.37D(1)條或第25.21D(1)條，我們在此確認，就上述所列股份類別而言，截至本月 ...

（ 於 香 港 註 冊 成 立 之 有 限 公 司 ） （ 股 份 代 號 ： 3613） 於 2026 年 2 月 11 日 舉 行 之 股 東 特 別 大 會 之 投 票 結 果 茲提述北京同仁堂國藥有限公司（「本公司」）兩者日期為 2026 年 1 月 21 日的股東 特別大會（「股東特別大會」）通函（「通函」）及通告（「通告」）。除另有界定 外，本公告所用詞彙與通函及通告所界定者具有相同涵義。 香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責 ， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明 ， 並 明 確 表 示 概 不 就 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 依 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任 。 BEIJING TONG REN TANG CHINESE MEDICINE COMPANY LIMITED 北 京 同 仁 堂 國 藥 有 限 公 司 承董事會命 北京同仁堂國藥有限公司 本公司董事（「董事」）會 ...

Core Insights - The Hong Kong Traditional Chinese Medicine (TCM) stocks showed strong performance, with China Traditional Chinese Medicine rising over 8% initially before settling at a 2.9% increase, while other stocks like Wei Yuan Tang and Tong Ren Tang Guo Yao also saw gains [1][2] Industry Developments - The Ministry of Industry and Information Technology, along with eight other departments, issued the "Implementation Plan for High-Quality Development of the TCM Industry (2026-2030)" [1] - By 2030, a collaborative development system for the entire TCM industry chain is expected to be initially formed, with enhanced stable supply capabilities for key TCM raw materials and significant improvements in digitalization and greening levels [1] - The plan emphasizes the use of artificial intelligence and big data to create knowledge graphs for classic formulas and experiences from renowned TCM practitioners [1] Policy Implications - Analysts view this plan as a systemic, long-term policy benefit for TCM stocks, marking a shift from "extensive growth" to "quality and value-driven" development [1] - The plan serves as a "general program" for the development of the TCM industry over the next five years, focusing on raising industry standards, encouraging innovation, and driving a profound supply-side reform [1]

Group 1 - The core viewpoint of the news is that the Chinese traditional medicine sector is experiencing a strong market response following the release of a new development plan by the Ministry of Industry and Information Technology and seven other departments, which aims to enhance the quality and innovation of the industry by 2030 [1] - The plan outlines that by 2030, a collaborative development system for the entire traditional Chinese medicine (TCM) industry chain will be initially formed, with a focus on stable supply of key TCM raw materials and significant improvements in digitalization and greening levels [1] - Analysts suggest that this plan represents a systematic and long-term policy benefit for TCM stocks, marking a shift from "extensive growth" to "quality and value-driven" growth, serving as a guiding framework for the development of the TCM industry over the next five years [1] Group 2 - The stock performance of TCM companies shows a positive trend, with China Traditional Chinese Medicine rising over 8% at one point, currently up by 2.9%, and other companies like Yuyuan Tang and Tong Ren Tang also experiencing gains [2] - Specific stock price changes include: Yuyuan Tang at 0.365 with a 5.80% increase, China Traditional Chinese Medicine at 2.130 with a 2.90% increase, and Fosen Pharmaceutical at 0.750 with a 1.35% increase [2] - Other companies such as Tong Ren Rong Guo Yao, Baiyun Mountain, Tong Ren Tang Technology, and Jilin Changlong Pharmaceutical also reported slight increases in their stock prices, indicating a broader positive sentiment in the TCM sector [2]

Core Viewpoint - The traditional Chinese medicine sector is experiencing active market performance, with several companies showing significant stock price increases amid broader market conditions [2] Company Performance - China Traditional Chinese Medicine (00570.HK) saw a stock price increase of 5.8%, reaching HKD 2.19 [2] - Yao Wang Tang (00897.HK) experienced a rise of 4.35%, with its stock priced at HKD 0.36 [2] - Tong Ren Tang Guo Yao (03613.HK) increased by 2.38%, trading at HKD 9.03 [2] - Tong Ren Tang Technology (01666.HK) rose by 1.83%, with a stock price of HKD 4.44 [2]

第 1 頁 共 10 頁 v 1.2.0 FF301 II. 已發行股份及/或庫存股份變動及足夠公眾持股量的確認 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 北京同仁堂國藥有限公司 呈交日期: 2026年2月3日 I. 法定/註冊股本變動 不適用 FF301 1. 股份分類 普通股 股份類別 不適用 於香港聯交所上市 (註1) 是 證券代號 (如上市) 03613 說明 已發行股份（不包括庫存股份）數目 庫存股份數目 已發行股份總數 上月底結存 837,100,000 0 837,100,000 增加 / 減少 (-) 0 0 本月底結存 837,100,000 0 837,100,000 第 2 頁 共 10 頁 v 1.2.0 FF301 III.已發行股份及/或庫存股份變動詳情 (A). 股份期權（根據發行人的股份期權計劃） 不適用 第 3 頁 共 10 頁 v 1.2.0 足夠公眾持股量的確認(註4) | 根據《主板上市規則》第13.32D(1)條或第19A.28D(1)條 ...